

# **Tendinopathy Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034**

<https://marketpublishers.com/r/T1EAA8F1AF AFEN.html>

Date: May 2024

Pages: 133

Price: US\$ 6,499.00 (Single User License)

ID: T1EAA8F1AF AFEN

## **Abstracts**

The 7 major tendinopathy markets reached a value of US\$ 11.3 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US\$ 14.7 Billion by 2034, exhibiting a growth rate (CAGR) of 2.35% during 2024-2034.

The tendinopathy market has been comprehensively analyzed in IMARC's new report titled "Tendinopathy Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Tendinopathy refers to a group of conditions characterized by damage, degeneration, or inflammation of tendons, which are thick, fibrous cords that connect muscles to bones. The disease can affect any tendon in the body, but it commonly occurs in the shoulders, elbows, wrists, knees, hips, and ankles. The most common symptoms of this illness include pain, impaired function, tenderness, swelling, stiffness, reduced range of motion, etc. The pain associated with the ailment typically worsens with movement or activity involving the affected tendon. The diagnosis of this disorder relies on a detailed medical history, including information about symptoms, onset, and aggravating factors. A physical examination may be conducted to assess the afflicted region for any signs of inflammation or localized tenderness. The healthcare provider may further perform various diagnostic procedures, such as X-rays, magnetic resonance imaging, ultrasounds, etc., to evaluate real-time images of the tendons. In some cases, blood workups may be required to check for markers of inflammation, like C-reactive protein and erythrocyte sedimentation rate, to confirm a diagnosis among patients.

The increasing cases of biomechanical imbalances on account of improper training techniques during sports, poor posture, structural abnormalities, etc., are primarily driving the tendinopathy market. In addition to this, the rising incidences of various

associated risk factors, such as trauma, injury, advancing age, certain systemic diseases, etc., are also creating a positive outlook for the market. Moreover, the widespread adoption of nonsteroidal anti-inflammatory drugs, including ibuprofen and naproxen, that help to reduce pain and inflammation in individuals suffering from tendinopathy is further bolstering the market growth. Apart from this, the escalating utilization of platelet-rich plasma therapy, which involves injecting a concentrated solution of the patient's own platelets into the affected tendon to promote tissue healing, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of orthotic devices, such as braces, splints, shoe inserts, etc., since they can provide support and relieve stress, is also augmenting the market growth. Furthermore, the inflating demand for extracorporeal shockwave therapy that aids in stimulating blood flow and enhancing tissue regeneration is expected to drive the tendinopathy market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the tendinopathy market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for tendinopathy and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the tendinopathy market in any manner.

### Time Period of the Study

Base Year: 2023

Historical Period: 2018-2023

Market Forecast: 2024-2034

### Countries Covered

United States

Germany

France

United Kingdom

Italy

Spain

Japan

### Analysis Covered Across Each Country

Historical, current, and future epidemiology scenario

Historical, current, and future performance of the tendinopathy market

Historical, current, and future performance of various therapeutic categories in the market

Sales of various drugs across the tendinopathy market

Reimbursement scenario in the market

In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current tendinopathy marketed drugs and late-stage pipeline drugs.

### In-Market Drugs

Drug Overview

Mechanism of Action

Regulatory Status

Clinical Trial Results

Drug Uptake and Market Performance

### Late-Stage Pipeline Drugs

Drug Overview

Mechanism of Action

Regulatory Status

Clinical Trial Results

Drug Uptake and Market Performance

Key Questions Answered in this Report:

Market Insights

How has the tendinopathy market performed so far and how will it perform in the coming years?

What are the markets shares of various therapeutic segments in 2023 and how are they

expected to perform till 2034?

What was the country-wise size of the tendinopathy market across the seven major markets in 2023 and what will it look like in 2034?

What is the growth rate of the tendinopathy market across the seven major markets and what will be the expected growth over the next ten years?

What are the key unmet needs in the market?

## Epidemiology Insights

What is the number of prevalent cases (2018-2034) of tendinopathy across the seven major markets?

What is the number of prevalent cases (2018-2034) of tendinopathy by age across the seven major markets?

What is the number of prevalent cases (2018-2034) of tendinopathy by gender across the seven major markets?

How many patients are diagnosed (2018-2034) with tendinopathy across the seven major markets?

What is the size of the tendinopathy patient pool (2018-2023) across the seven major markets?

What would be the forecasted patient pool (2024-2034) across the seven major markets?

What are the key factors driving the epidemiological trend of tendinopathy?

What will be the growth rate of patients across the seven major markets?

## Tendinopathy: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

What are the current marketed drugs and what are their market performance?

What are the key pipeline drugs and how are they expected to perform in the coming years?

How safe are the current marketed drugs and what are their efficacies?

How safe are the late-stage pipeline drugs and what are their efficacies?

What are the current treatment guidelines for tendinopathy drugs across the seven major markets?

Who are the key companies in the market and what are their market shares?

What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the tendinopathy market?

What are the key regulatory events related to the tendinopathy market?

What is the structure of clinical trial landscape by status related to the tendinopathy market?

What is the structure of clinical trial landscape by phase related to the tendinopathy market?

What is the structure of clinical trial landscape by route of administration related to the tendinopathy market?

## Contents

### **1 PREFACE**

### **2 SCOPE AND METHODOLOGY**

- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
  - 2.3.1 Primary Sources
  - 2.3.2 Secondary Sources
- 2.4 Market Estimation
  - 2.4.1 Bottom-Up Approach
  - 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology

### **3 EXECUTIVE SUMMARY**

### **4 TENDINOPATHY - INTRODUCTION**

- 4.1 Overview
- 4.2 Regulatory Process
- 4.3 Epidemiology (?2018-2023?) and Forecast (?2024-2034?)
- 4.4 Market Overview (?2018-2023?) and Forecast (?2024-2034?)
- 4.5 Competitive Intelligence

### **5 TENDINOPATHY - DISEASE OVERVIEW**

- 5.1 Introduction
- 5.2 Symptoms and Diagnosis
- 5.3 Pathophysiology
- 5.4 Causes and Risk Factors
- 5.5 Treatment

### **6 PATIENT JOURNEY**

### **7 TENDINOPATHY - EPIDEMIOLOGY AND PATIENT POPULATION**

- 7.1 Epidemiology - Key Insights

- 7.2 Epidemiology Scenario - Top 7 Markets
  - 7.2.1 Epidemiology Scenario (?2018-2023?)
  - 7.2.2 Epidemiology Forecast (?2024-2034?)
  - 7.2.3 Epidemiology by Age (?2018-2034?)
  - 7.2.4 Epidemiology by Gender (?2018-2034?)
  - 7.2.5 Diagnosed Cases (?2018-2034?)
  - 7.2.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.3 Epidemiology Scenario - United States
  - 7.3.1 Epidemiology Scenario (?2018-2023?)
  - 7.3.2 Epidemiology Forecast (?2024-2034?)
  - 7.3.3 Epidemiology by Age (?2018-2034?)
  - 7.3.4 Epidemiology by Gender (?2018-2034?)
  - 7.3.5 Diagnosed Cases (?2018-2034?)
  - 7.3.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.4 Epidemiology Scenario - Germany
  - 7.4.1 Epidemiology Scenario (?2018-2023?)
  - 7.4.2 Epidemiology Forecast (?2024-2034?)
  - 7.4.3 Epidemiology by Age (?2018-2034?)
  - 7.4.4 Epidemiology by Gender (?2018-2034?)
  - 7.4.5 Diagnosed Cases (?2018-2034?)
  - 7.4.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.5 Epidemiology Scenario - France
  - 7.5.1 Epidemiology Scenario (?2018-2023?)
  - 7.5.2 Epidemiology Forecast (?2024-2034?)
  - 7.5.3 Epidemiology by Age (?2018-2034?)
  - 7.5.4 Epidemiology by Gender (?2018-2034?)
  - 7.5.5 Diagnosed Cases (?2018-2034?)
  - 7.5.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.6 Epidemiology Scenario - United Kingdom
  - 7.6.1 Epidemiology Scenario (?2018-2023?)
  - 7.6.2 Epidemiology Forecast (?2024-2034?)
  - 7.6.3 Epidemiology by Age (?2018-2034?)
  - 7.6.4 Epidemiology by Gender (?2018-2034?)
  - 7.6.5 Diagnosed Cases (?2018-2034?)
  - 7.6.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.7 Epidemiology Scenario - Italy
  - 7.7.1 Epidemiology Scenario (?2018-2023?)
  - 7.7.2 Epidemiology Forecast (?2024-2034?)
  - 7.7.3 Epidemiology by Age (?2018-2034?)

- 7.7.4 Epidemiology by Gender (?2018-2034?)
- 7.7.5 Diagnosed Cases (?2018-2034?)
- 7.7.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.8 Epidemiology Scenario - Spain
  - 7.8.1 Epidemiology Scenario (?2018-2023?)
  - 7.8.2 Epidemiology Forecast (?2024-2034?)
  - 7.8.3 Epidemiology by Age (?2018-2034?)
  - 7.8.4 Epidemiology by Gender (?2018-2034?)
  - 7.8.5 Diagnosed Cases (?2018-2034?)
  - 7.8.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.9 Epidemiology Scenario - Japan
  - 7.9.1 Epidemiology Scenario (?2018-2023?)
  - 7.9.2 Epidemiology Forecast (?2024-2034?)
  - 7.9.3 Epidemiology by Age (?2018-2034?)
  - 7.9.4 Epidemiology by Gender (?2018-2034?)
  - 7.9.5 Diagnosed Cases (?2018-2034?)
  - 7.9.6 Patient Pool/Treated Cases (?2018-2034?)

## **8 TENDINOPATHY - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES**

- 8.1 Guidelines, Management and Treatment
- 8.2 Treatment Algorithm

## **9 TENDINOPATHY - UNMET NEEDS**

## **10 TENDINOPATHY - KEY ENDPOINTS OF TREATMENT**

## **11 TENDINOPATHY - MARKETED PRODUCTS**

- 11.1 List of Tendinopathy Marketed Drugs Across the Top 7 Markets
  - 11.1.1 Drug Name – Company Name
    - 11.1.1.1 Drug Overview
    - 11.1.1.2 Mechanism of Action
    - 11.1.1.3 Regulatory Status
    - 11.1.1.4 Clinical Trial Results
    - 11.1.1.5 Sales Across Major Markets

Kindly note that the complete list of marketed drugs has been provided in the report.



## **12 TENDINOPATHY - PIPELINE DRUGS**

### 12.1 List of Tendinopathy Pipeline Drugs Across the Top 7 Markets

#### 12.1.1 Drug Name – Company Name

##### 12.1.1.1 Drug Overview

##### 12.1.1.2 Mechanism of Action

##### 12.1.1.3 Clinical Trial Results

##### 12.1.1.4 Safety and Efficacy

##### 12.1.1.5 Regulatory Status

Kindly note that the complete list of pipeline drugs has been provided in the report.

## **13. TENDINOPATHY - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS**

## **14. TENDINOPATHY – CLINICAL TRIAL LANDSCAPE**

### 14.1 Drugs by Status

### 14.2 Drugs by Phase

### 14.3 Drugs by Route of Administration

### 14.4 Key Regulatory Events

## **15 TENDINOPATHY - MARKET SCENARIO**

### 15.1 Market Scenario - Key Insights

### 15.2 Market Scenario - Top 7 Markets

#### 15.2.1 Tendinopathy - Market Size

##### 15.2.1.1 Market Size (?2018-2023?)

##### 15.2.1.2 Market Forecast (?2024-2034?)

#### 15.2.2 Tendinopathy - Market Size by Therapies

##### 15.2.2.1 Market Size by Therapies (?2018-2023?)

##### 15.2.2.2 Market Forecast by Therapies (?2024-2034?)

### 15.3 Market Scenario - United States

#### 15.3.1 Tendinopathy - Market Size

##### 15.3.1.1 Market Size (?2018-2023?)

##### 15.3.1.2 Market Forecast (?2024-2034?)

#### 15.3.2 Tendinopathy - Market Size by Therapies

##### 15.3.2.1 Market Size by Therapies (?2018-2023?)

##### 15.3.2.2 Market Forecast by Therapies (?2024-2034?)

#### 15.3.3 Tendinopathy - Access and Reimbursement Overview

- 15.4 Market Scenario - Germany
  - 15.4.1 Tendinopathy - Market Size
    - 15.4.1.1 Market Size (?2018-2023?)
    - 15.4.1.2 Market Forecast (?2024-2034?)
  - 15.4.2 Tendinopathy - Market Size by Therapies
    - 15.4.2.1 Market Size by Therapies (?2018-2023?)
    - 15.4.2.2 Market Forecast by Therapies (?2024-2034?)
  - 15.4.3 Tendinopathy - Access and Reimbursement Overview
- 15.5 Market Scenario - France
  - 15.5.1 Tendinopathy - Market Size
    - 15.5.1.1 Market Size (?2018-2023?)
    - 15.5.1.2 Market Forecast (?2024-2034?)
  - 15.5.2 Tendinopathy - Market Size by Therapies
    - 15.5.2.1 Market Size by Therapies (?2018-2023?)
    - 15.5.2.2 Market Forecast by Therapies (?2024-2034?)
  - 15.5.3 Tendinopathy - Access and Reimbursement Overview
- 15.6 Market Scenario - United Kingdom
  - 15.6.1 Tendinopathy - Market Size
    - 15.6.1.1 Market Size (?2018-2023?)
    - 15.6.1.2 Market Forecast (?2024-2034?)
  - 15.6.2 Tendinopathy - Market Size by Therapies
    - 15.6.2.1 Market Size by Therapies (?2018-2023?)
    - 15.6.2.2 Market Forecast by Therapies (?2024-2034?)
  - 15.6.3 Tendinopathy - Access and Reimbursement Overview
- 15.7 Market Scenario - Italy
  - 15.7.1 Tendinopathy - Market Size
    - 15.7.1.1 Market Size (?2018-2023?)
    - 15.7.1.2 Market Forecast (?2024-2034?)
  - 15.7.2 Tendinopathy - Market Size by Therapies
    - 15.7.2.1 Market Size by Therapies (?2018-2023?)
    - 15.7.2.2 Market Forecast by Therapies (?2024-2034?)
  - 15.7.3 Tendinopathy - Access and Reimbursement Overview
- 15.8 Market Scenario - Spain
  - 15.8.1 Tendinopathy - Market Size
    - 15.8.1.1 Market Size (?2018-2023?)
    - 15.8.1.2 Market Forecast (?2024-2034?)
  - 15.8.2 Tendinopathy - Market Size by Therapies
    - 15.8.2.1 Market Size by Therapies (?2018-2023?)
    - 15.8.2.2 Market Forecast by Therapies (?2024-2034?)

- 15.8.3 Tendinopathy - Access and Reimbursement Overview
- 15.9 Market Scenario - Japan
  - 15.9.1 Tendinopathy - Market Size
    - 15.9.1.1 Market Size (?2018-2023?)
    - 15.9.1.2 Market Forecast (?2024-2034?)
  - 15.9.2 Tendinopathy - Market Size by Therapies
    - 15.9.2.1 Market Size by Therapies (?2018-2023?)
    - 15.9.2.2 Market Forecast by Therapies (?2024-2034?)
  - 15.9.3 Tendinopathy - Access and Reimbursement Overview

## **16 TENDINOPATHY - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS**

## **17 TENDINOPATHY MARKET - SWOT ANALYSIS**

- 17.1 Strengths
- 17.2 Weaknesses
- 17.3 Opportunities
- 17.4 Threats

## **18 TENDINOPATHY MARKET – STRATEGIC RECOMMENDATIONS**

## **19 APPENDIX**

## I would like to order

Product name: Tendinopathy Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

Product link: <https://marketpublishers.com/r/T1EAA8F1AF AFEN.html>

Price: US\$ 6,499.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/T1EAA8F1AF AFEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

